RAPGEF2

Across TCGA pan-cancer cohorts, RAPGEF2 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of RAPGEF2’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where RAPGEF2 RNA is repressed in tumor relative to normal tissue. In most cancer types RAPGEF2 is over-expressed in tumor, although a few such as THCA and LUAD show the opposite, repressed pattern.

THCA, KIRC, and LUAD are the cancer types where RAPGEF2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RAPGEF2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	All	II,III,IV	−0.886	<.001	9	view →
KIRC	Female	All	+0.708	<.001	8	view →
LUAD	Female	II,III,IV	−0.858	<.001	7	view →
LUSC	Female	II,III,IV	−1.717	<.001	6	view →
BRCA	All	III,IV	−0.804	<.001	6	view →
COAD	Female	All	−0.614	.001	4	view →
KICH	All	II,III,IV	+0.605	.004	4	view →
UCEC	All	All	−0.565	.003	4	view →
PRAD	All	All	+0.312	.008	2	view →
STAD	Male	II,III,IV	+0.636	.039	1	view →
READ	Female	All	−0.592	.025	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

RAPGEF2–THCA

Open the THCA breakdown →